Hiroya Asou

4.7k total citations · 2 hit papers
70 papers, 3.9k citations indexed

About

Hiroya Asou is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Hiroya Asou has authored 70 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 24 papers in Oncology and 23 papers in Hematology. Recurrent topics in Hiroya Asou's work include Acute Myeloid Leukemia Research (20 papers), Retinoids in leukemia and cellular processes (12 papers) and Lymphoma Diagnosis and Treatment (12 papers). Hiroya Asou is often cited by papers focused on Acute Myeloid Leukemia Research (20 papers), Retinoids in leukemia and cellular processes (12 papers) and Lymphoma Diagnosis and Treatment (12 papers). Hiroya Asou collaborates with scholars based in Japan, United States and Denmark. Hiroya Asou's co-authors include H. Phillip Koeffler, Jonathan Said, Kozo Koshizuka, Elizabeth A. Williamson, Elena Elstner, David Heber, Carsten Müller‐Tidow, Dorothy Park, Peter Shintaku and Tetsuya Kubota and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Hiroya Asou

67 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

1998 719 citations Hiroya Asou, H. Phillip Koeffler et al. profile →
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

1998 534 citations Hiroya Asou, H. Phillip Koeffler et al. PubMed profile →

Peers

Countries citing papers authored by Hiroya Asou

Since Specialization

Citations

This map shows the geographic impact of Hiroya Asou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroya Asou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroya Asou more than expected).

Fields of papers citing papers by Hiroya Asou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroya Asou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroya Asou. The network helps show where Hiroya Asou may publish in the future.

Co-authorship network of co-authors of Hiroya Asou

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroya Asou. A scholar is included among the top collaborators of Hiroya Asou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroya Asou. Hiroya Asou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world assessment to estimate multiple attributes related to treatment cost driver for mantle cell lymphoma in Japan by econometric modeling 2025 ·BMC Health Services Research ·(unknown), Shinichi Makita, Hiroya Asou, (unknown), (unknown), (unknown), Seok-Won Kim, (unknown)	0
2	Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structural equation model (SEM) analysis 2012–2022 2025 ·PLoS ONE ·(unknown), Shinichi Makita, Hiroya Asou, (unknown), Wen Shi Lee, (unknown), (unknown), (unknown), Seok-Won Kim, Todd D. Taylor	0
3	Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial 2024 ·Future Oncology ·(unknown), (unknown), Hiroya Asou, Hiroyuki Matsuda, (unknown)	1
4	Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study 2021 ·Cancer Medicine ·Toshihiko Doi, Noboru Yamamoto, Yoichi Naito, Yasutoshi Kuboki, Takafumi Koyama, Yongzhe Piao, (unknown), Hiroya Asou, Kōichi Inoue, Shunsuke Kondo	7
5	Comparison between turbo spin-echo and echo planar diffusion-weighted imaging of the female pelvis with 3T MRI 2021 ·Acta Radiologica Open ·Takeshi Yoshizako, Rika Yoshida, Hiroya Asou, Megumi Nakamura, Hajime Kitagaki	4
6	A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan 2021 ·Gastric Cancer ·(unknown), (unknown), Soshi Nagaoka, Yongzhe Piao, Kensei Yamaguchi, Hiroya Asou	3
7	Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer 2020 ·Investigational New Drugs ·Shunsuke Kondo, Masaomi Tajimi, (unknown), Kōichi Inoue, Hiroya Asou, (unknown), Volker Wacheck, Toshihiko Doi	5
8	Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations 2020 ·Human Cell ·Fumio Kasai, Hiroya Asou, (unknown), Kazuhiko Kobayashi, (unknown), Motonobu Satoh, Arihiro Kohara, Yasuhiko Kaneko, M Kawamura	10
9	Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer 2016 ·Cancer Chemotherapy and Pharmacology ·Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, Yuko Tanabe, Satoru Iwasa, Akihiko Shimomura, Shigehisa Kitano, K. OGASAWARA, P. Kellie Turner, (unknown), Hiroya Asou, Edward M. Chan, Noboru Yamamoto	50
10	Haploinsufficiency of SAMD9L, an Endosome Fusion Facilitator, Causes Myeloid Malignancies in Mice Mimicking Human Diseases with Monosomy 7 2013 ·Cancer Cell ·Akiko Nagamachi, Hirotaka Matsui, Hiroya Asou, (unknown), Daisuke Aki, Akinori Kanai, Keiyo Takubo, Toshio Suda, Takuro Nakamura, Linda Wolff, Hiroaki Honda, Toshiya Inaba	103
11	Poly-ADP Ribosylation of Miki by tankyrase-1 Promotes Centrosome Maturation 2012 ·Molecular Cell ·(unknown), Hirotaka Matsui, Hiroya Asou, Akiko Nagamachi, Daisuke Aki, Hiroaki Honda, Shin’ichiro Yasunaga, Yoshihiro Takihara, Tadashi Yamamoto, Shunsuke Izumi, Miho Ohsugi, Toshiya Inaba	51
12	Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma 2010 ·British Journal of Cancer ·Lin Jin, Yoko Tabe, Shinya Kimura, (unknown), Junya Kuroda, Hiroya Asou, Toshiya Inaba, Marina Konopleva, Michael Andreeff, Takashi Miida	21
13	Establishment of the acute myeloid leukemia cell line Kasumi‐6 from a patient with a dominant‐negative mutation in the DNA‐binding region of the C/EBPα gene 2002 ·Genes Chromosomes and Cancer ·Hiroya Asou, Adrian F. Gombart, Seisho Takeuchi, Hideo Tanaka, Maki Tanioka, Hirotaka Matsui, Akiro Kimura, Toshiya Inaba, H. Phillip Koeffler	24
14	Detection of Translocation 8;21 on Interphase Cells from Acute Myelocytic Leukemia by Fluorescence In Situ Hybridization and Its Clinical Application 1999 ·Cancer Genetics and Cytogenetics ·Kimio Tanaka, (unknown), Hiroya Asou, Kimiko Shimizu, Misao Ohki, Taiichi Kyo, Hiroo Dohy, Nanao Kamada	3
15	Establishment of an Undifferentiated Leukemia Cell Line (Kasumi‐3) with t(3;7)(q27;q22) and Activation of the EVI1 Gene 1996 ·Japanese Journal of Cancer Research ·Hiroya Asou, Kazumi Suzukawa, Kenkichi Kita, Kazunori Nakase, (unknown), Kazuhiro Morishita, Nanao Kamada	29
16	Hidden monosomy 7 in acute myeloid leukemia and myelodysplastic syndrome detected by interphase fluorescence in situ hybridization 1996 ·Leukemia Research ·(unknown), (unknown), Chendil Damodaran, Hiroya Asou, (unknown), Hiroo Dohy, (unknown)	22
17	A specific chromosome abnormality of t(4;12)(qll‐12;pl3) in CD7⁺ acute leukaemia 1995 ·British Journal of Haematology ·(unknown), Hiroya Asou, (unknown), Hideki Asaoku, Koji Iwato, Hiroo Dohy, Kenji Oda, Yuka Harada, Kenkichi Kita, Nanao Kamada	10
18	Emergence of karyotypically unrelated clone in remission of de novo acute myeloblastic leukaemias 1995 ·British Journal of Haematology ·(unknown), Hiroya Asou, Taiichi Kyo, Hideki Asaoku, Hiroo Dohy, Mariko Eguchi, Satoshi Tashiro, Kimio Tanaka, Nanao Kamada	4
19	Detection of PML/Retinoic Acid Receptor α Gene Rearrangements by Polymerase Chain Reaction Using Genomic DNA in Patients with Acute Promyelocytic Leukemia 1993 ·Japanese Journal of Cancer Research ·Satoshi Tashiro, (unknown), Hiroya Asou, (unknown), Hiroo Dohy, (unknown), Nanao Kamada	3
20	Cytogenetic 2; 18 and 18; 22 translocation in chronic lymphocytic leukemia with juxtaposition of bcl-2 and immunoglobulin light chain genes. 1992 ·PubMed ·Satoshi Tashiro, Miho Takechi, Hiroya Asou, (unknown), (unknown), Hiroo Dohy, Masahiko Kikuchi, N Kamada, Yuji Tsujimoto	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact